Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:ENLV

Enlivex Therapeutics Earnings Date & Estimates

Enlivex Therapeutics logo
$2.70 +0.10 (+3.72%)
Closing price 10/27/2026 03:58 PM Eastern
Extended Trading
$2.65 -0.05 (-1.85%)
As of 10/27/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enlivex Therapeutics is estimated to report earnings on Friday, November 13, 2026.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Enlivex Therapeutics

Enlivex Therapeutics is expected to post earnings of -$0.28 per share. In the same quarter a year earlier Enlivex Therapeutics reported -$22.1810 per share. Enlivex Therapeutics last reported on November 14, 2025, posting -$22.1810 per share and beating the -$28.80 consensus estimate. Enlivex Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.28
Prior-Year EPS
-$22.1810

Recent Track Record

Last Reported
Q3 2025
Last Quarter EPS
-$22.1810 (Beat by +$6.6190)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Earnings Call

Enlivex Therapeutics Earnings FAQ

Enlivex Therapeutics (NASDAQ:ENLV) is estimated to report earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Enlivex Therapeutics to post earnings of -$0.28 per share for the quarter.

Enlivex Therapeutics Earnings Headlines

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
October 27 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3388940/0/en/enlivex-announces-receipt-of-delisting-notice-from-nasdaq-intends-to-appeal.html
Enlivex Therapeutics Ltd. announces 1-for-16 reverse share split effective October 27, 2026
October 22, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/enlivex-therapeutics-ltd-announces-1-for-16-reverse-share-split-effective-october-27-2026/ar-AA2fT5CR
DO YOU LIVE HERE? ⬇️
Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as 100,000 homes, and one Virginia homeowner saw his bill jump from $100 to $281 in a single month. Elon Musk has filed a plan with the FCC to move data centers out of cities entirely, a move backed by President Trump. One lesser-known, publicly traded company trading under $100 a share may sit at the center of that shift.tc pixel
 |  Paradigm Press (Ad)
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386960/0/en/enlivex-announces-1-for-16-reverse-share-split-to-be-effective-october-27-2026.html
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
October 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383415/0/en/enlivex-announces-cost-reduction-plan-to-focus-resources-on-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis.html
Enlivex Therapeutics (ENLV)
September 25, 2026  |  es.investing.comhttps://es.investing.com/equities/enlivex-therapeutics-ltd-balance-sheet
See More Enlivex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email.

About Enlivex Therapeutics

Enlivex Therapeutics (NASDAQ:ENLV) (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression.

Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages. The company has investigated Allocetra-OTS in severe sepsis and other inflammatory conditions, including COVID-19-related disease, and has pursued additional applications in immunology.

The company was founded in Israel and conducts its research and clinical development activities primarily in Israel, while seeking to develop therapies for international markets. Enlivex was established by physician-scientist Dr. Dror Mevorach, who has been associated with the development of the company’s immune-modulating technology. Its programs remain subject to clinical testing and regulatory review before any potential commercialization.

View Enlivex Therapeutics Profile
Earnings Tools